NET PROFIT (x1000 SEK)
EMPLOYEES
Eurofins Biopharma Product Testing Denmark A/S
Closing information (x1000 SEK)
| Closing information | 2024/12 | 2021/12 | 2020/12 |
| Turnover |
0
|
0
|
0 |
| Earnings before taxes |
21,224
|
20,397
|
16,876 |
| Total assets |
133,417
|
67,817
|
60,552 |
| Current assets |
91,966
|
55,095
|
50,537 |
| Current liabilities |
93,312
|
29,548
|
30,437 |
| Equity capital |
34,721
|
25,510
|
17,532 |
| - share capital |
1,078
|
963
|
944 |
| Employees (average) |
75
|
75
|
75 |
Financial ratios
| Fiscal year | 2024/12 | 2021/12 | 2020/12 |
| Solvency |
26.0%
|
37.6%
|
29.0% |
| Turnover per employee |
0
|
0
|
0 |
| Profit as a percentage of turnover | |||
| Return on assets (ROA) | |||
| Current ratio |
98.6%
|
186.5%
|
166.0% |
| Return on equity (ROE) |
61.1%
|
80.0%
|
96.3% |
| Change turnover |
0
|
0
|
0 |
| Change turnover % | |||
| Chg. No. of employees |
0
|
0
|
0 |
| Chg. No. of employees % |
0%
|
0%
|
0% |
Total value of public sale
| Fiscal year | 2024/12 | 2021/12 | 2020/12 |
| Total value of public sale |
0
|
0
|
0 |
Closing figures are converted to the currency above at the exchange rate of the closing date. Source for the exchange rates: Sveriges Riksbank
The closing information is gathered directly from the companies or from Creditsafe.